Top etanercept Articles in Internal Medicine

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 10/27/2009

Giardina AR et al. – The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2–year ... more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. [more...]

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis
Dermatology, 10/23/2009

Reich K et al. – Patients with moderate–to–severe psoriasis entered this trial with serious PRO impairment. At week 12, etanercept 50 mg QW provided ... improvements compared with placebo. After 24 weeks of etanercept, the patients' serious PRO impairment had largely abated. [more...]

Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Cochrane Reviews, 10/12/2009

Singh JA et al. – Based upon indirect comparisons, anakinra seemed less efficacious than etanercept, adalimumab and rituximab and etanercept seemed to cause fewer withdrawals due to adverse events than adalimumab, anakinra and infliximab. Significant heterogeneity in [more...]

Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study
Zeitschrift für Rheumatologie, 10/07/2009

Schulze–Koops H et al. – The TEMPO study has shown that the combination of etanercept and methotrexat (MTX) in the treatment of rheumatoid arthritis (RA) is superior to [more...]

Early subcutaneous administration of etanercept (ENBREL) prevents from hyperoxia-induced lung injury
Experimental Lung Research, 11/09/2009

Guthmann F et al. – The authors assume that subcutaneous administration of etanercept might be suitable to prevent acute lung injury and its sequelae induced by hyperoxic ventilation of [more...]

Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/2009

receiving adalimumab or infliximab had higher risk than those treated with etanercept: SIR = 4.1 (2.3–7.1) and 3.6 (2.3–5.6) versus 0.9 (0.4–1.8) Exposure to adalimumab or infliximab versus etanercept independent risk factor for lymphoma in case-control study: odds ratio=4.7 (1.3–17.7) and [more...]

Scoring evaluation for histopathological features of synovium in patients with rheumatoid arthritis during anti-tumor necrosis factor therapy
Rheumatology International, 10/21/2009

during total knee arthroplasty (TKA) from 42 RA patients (12 men, 30 women) 21 patients were given anti-TNF &alpha (infliximab, n = 12; etanercept, n = 9), while the remaining 21 RA patients were given no such agents Histopathological findings compared between specimens from these [more...]

Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting
Amgen, 10/19/2009

Amgen and Pfizer, announced new scientific data about ENBREL being presented at the 2009 American College of Rheumatology Scientific Meeting in Philadelphia, Pa., from Oct. 2009. These [more...]

Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis
Dermatology, 10/22/2009

Anis A et al. – TNF inhibitors were more effective than T cell agents; adalimumab and infliximab were more effective than systemic therapies and etanercept. Evidence–based comparisons support patient and physician decisions. [more...]

A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept
Rheumatology International, 10/16/2009

Ishii W et al. – Systemic reactive amyloid A (AA) amyloidosis is one of the critical complications associated with rheumatoid arthritis [more...]